Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Prime Medicine, Inc. (Nasdaq: PRME) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a public biotechnology company, Prime Medicine uses forms such as Form 8-K, Form 10-Q, Form 10-K and proxy statements to report material events, financial results, governance matters and other information related to its Prime Editing gene editing platform and pipeline.
Recent Form 8-K filings for Prime Medicine have covered topics such as quarterly financial results and business highlights, preliminary cash and investment balances, underwritten public offerings of common stock, option repricing approvals, changes in executive leadership, and the posting of updated corporate presentations. These filings help investors understand how the company is funding research and development for programs in Wilson’s Disease, Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis and other areas, as well as how it manages equity compensation and corporate governance.
Definitive proxy materials, such as the company’s DEF 14A, describe matters submitted to stockholders, including proposals related to equity plans and special meetings. Over time, periodic reports on Forms 10-K and 10-Q (when available) provide more detailed information on Prime Medicine’s operations, risk factors, research and development expenses, and other aspects of its business as a biotechnology issuer focused on Prime Editing-based therapies.
On Stock Titan, Prime Medicine filings are updated as they are made available through EDGAR. AI-powered tools summarize key points from lengthy documents, helping users quickly identify items such as new financing arrangements, changes in leadership roles, special stockholder meetings, and other material events disclosed in Forms 8-K and related exhibits. Users can also review filings that may include information about stock-based compensation, equity offerings, and other capital structure changes relevant to PRME shares.
On 01 Aug 2025, Prime Medicine, Inc. (PRME) received a Form 4 from its largest outside shareholder group, ARCH Venture Partners. Affiliate ARCH Venture Fund XII, L.P. executed an open-market purchase of 3,030,300 common shares at $3.30 (Transaction Code P). The buy lifts that fund’s direct position to 6,230,300 shares. Two related funds—ARCH Venture Fund X, L.P. and ARCH Venture Fund X Overage, L.P.—each continue to hold 6,128,297 shares. Taken together, the ARCH funds now report indirect beneficial ownership of more than 18 million PRME shares, maintaining their status as a 10% owner.
No derivative securities were involved and no sales were reported. The filing is part of a joint submission; a separate Form 4 covers shares held personally by ARCH co-founder Robert Nelsen. The sizable purchase at a single-digit share price signals continued confidence and long-term support from a strategic life-science investor.
Prime Medicine (PRME) – Form 4 insider transaction filed 08/01/2025. ARCH Venture entities, collectively 10% owners, disclosed a purchase of 3,030,300 common shares at $3.30 per share (approx. $10.0 million). The buyer of record is ARCH Venture Fund XII, L.P.
Post-transaction indirect holdings stand at:
- ARCH Venture Fund X, L.P.: 6,128,297 shares (unchanged)
- ARCH Venture Fund X Overage, L.P.: 6,128,297 shares (unchanged)
- ARCH Venture Fund XII, L.P.: 6,230,300 shares (up from zero disclosed in this filing)
Total indirect ownership across the reporting group rises to roughly 18.5 million shares. The filing is one of two joint reports; Robert Nelsen is filing separately for his direct holdings.
Key take-away: A sizable open-market purchase by a long-term venture backer at a depressed price signals increased confidence in PRME’s prospects and tightens insider alignment with public shareholders.
FAQ
What is the current stock price of Prime Medicine (PRME)?
What is the market cap of Prime Medicine (PRME)?
